Bone Marrow Derived Stem Cells Mobilization for Treatment of Abnormal Endometrium

Recruiting now · Early Phase 1

Conditions studied: Asherman Syndrome, Atrophic Endometrium, Recurrent Implantation Failure

In brief

This study will assess the use of autologous bone marrow stem cells mobilization using 1,1'-\[1,4-phenylenebis-(methylene)\]-bis-1,4,8,11-tetraazacyclotetradecane (PLERIXAFOR) as an effective medical therapy for the treatment of Asherman's Syndrome (AS), Atrophic Endometrium (AE) and Recurrent Implantation Failure (RIF).

Key facts

Study ID

NCT05343572

Run by

Hugh Taylor

People needed

90

Starts

2023-11-01

Expected to finish

2027-12-01

Last updated by the study team

2025-11-12

Who can join

Age: 18 and older, up to 40. Sex: female. Healthy volunteers: accepted.

You may qualify if…

• Healthy, non pregnant females
• ages ≥18 and ≤40 years old at time of enrollment
• with either AS, AE, or RIF
• For AS: surgical history of intrauterine trauma/infection, hypo/amenorrhea, intra-uterine adhesions
• for AE: US documentation of persistent, <6mm endometrial thickness
• for RIF: failure to achieve a clinical pregnancy after transfer of at least four good-quality embryos in a minimum of three fresh or frozen cycles in a woman under 40 years and currently being treated at Yale Fertility Clinic

You may not qualify if…

• Presence of hydrosalpinx (diagnosed by radiographic or ultrasound imaging)
• Endometriosis (diagnosed by previous surgery,)
• Diminished ovarian reserve (AMH<1ng/ml or follicle stimulating hormone (FSH)>10)
• History of genital tuberculosis or any ultrasound evidence of congenital uterine anomaly
• Submucous or intracavitary fibroid, polyps
• Currently pregnant
• Personal history of thrombophilia or sickle cell disease
• Inability to provide informed consent

Where it is running

• Yale Fertility Center — Orange, Connecticut, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.